Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial

Pierre Véra, S. Thureau, F. Le Tinier, Philippe Chaumet‐Riffaud, Sébastien Hapdey, H. Kolesnikov-Gauthier, É. Martin, Alina Berriolo-Riedinger, N. Pourel, Jean Marc Broglia, Pierre Boissellier, Sophie Guillemard, Naji Salem, I. Brenot-Rossi, C. Le Péchoux, Céline Berthold, Etienne Giroux‐Leprieur, Damien Moreau, S. Guillerm, Khadija Benali, Laurent Tessonnier, Clarisse Audigier-Valette, D. Lerouge, Elske Quak, Carole Massabeau, F. Courbon, P Moisson, Anne Larrouy, Romain Modzelewski, P. Gouel, N. Ghazzar, Alexandra Langlais, Elodie Amour, Gérard Zalcman, Philippe Giraud